Q1 Earnings Estimate for MediWound Issued By HC Wainwright

MediWound Ltd. (NASDAQ:MDWD) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of MediWound in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their prior estimate of ($0.56). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound’s Q2 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at $0.80 EPS.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the firm posted ($0.19) earnings per share.

A number of other brokerages also recently commented on MDWD. Craig Hallum began coverage on MediWound in a research report on Friday, February 28th. They issued a “buy” rating and a $39.00 price objective for the company. StockNews.com raised MediWound to a “sell” rating in a research note on Friday.

MediWound Stock Performance

MDWD stock opened at $16.27 on Monday. The company has a 50 day moving average price of $18.17 and a two-hundred day moving average price of $17.59. The stock has a market capitalization of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82. MediWound has a one year low of $12.78 and a one year high of $24.00.

Hedge Funds Weigh In On MediWound

Large investors have recently modified their holdings of the company. MetLife Investment Management LLC acquired a new stake in MediWound in the 3rd quarter valued at $89,000. Investor AB purchased a new stake in shares of MediWound during the 3rd quarter valued at about $15,750,000. Point72 Asset Management L.P. acquired a new position in MediWound during the 3rd quarter worth approximately $212,000. State Street Corp boosted its holdings in MediWound by 219.6% in the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 45,529 shares during the period. Finally, Barclays PLC grew its position in MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 8,449 shares in the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.